# 🚀 Sen-Jam Expands Galaxy Through a New DrugBank Licensing Partnership | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/361981
- Entity ID: wefunder:feed_item:361981
- Published at: 2026-08-01 19:23:38 UTC
- Updated at: 2026-08-01 19:44:12 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors & Community,I am excited to share an important milestone in Sen-Jam’s evolution:🔬 Sen-Jam Pharmaceutical has entered into a licensing partnership with DrugBank, providing our team with access to one of the world’s most comprehensive and scientifically curated drug knowledge platforms.This represents a significant step forward in the development of Atlas—the drug-discovery engine within our Galaxy AI platform.DrugBank brings together extensive information on approved and investigational drugs, mechanisms of action, molecular targets, pathways, interactions, and other pharmacological relationships. Integrating this knowledge into Atlas will allow us to evaluate combinations of two and three existing compounds more systematically—searching for overlooked therapeutic opportunities that align with Sen-Jam’s expertise in inflammation resolution.Why is this important to Sen-Jam’s long-term enterprise value?🌐 A dramatically larger discovery universeRather than relying solely on a limited number of internally identified candidates, Atlas can systematically explore a much broader universe of potential drug combinations and therapeutic applications. This creates more opportunities—or “shots on goal”—to identify valuable new medicines.⚡ Greater speed and capital efficiencyAtlas is designed to computationally prioritize the most promising opportunities before we commit significant capital to laboratory, preclinical, or clinical development. The goal is straightforward: discover faster, reduce development costs, and increase the probability of success.🛡️ Ownership of the value Sen-Jam createsImportantly, the agreement protects Sen-Jam’s ability to own and commercialize the therapeutic discoveries and other qualifying results we create through Atlas.DrugBank provides the data foundation. Sen-Jam’s algorithms, scientific judgment, combination intelligence, and development capabilities create the differentiated value.🤝 New partnership and revenue opportunitiesSubject to the agreement’s terms, Sen-Jam can also use Atlas to perform controlled analytical work for strategic partners and their clients—without providing access to DrugBank’s underlying data.Over time, this capability could support: Paid analytical and discovery projects Strategic partnerships Co-development programs New licensing opportunities Expansion of Sen-Jam’s proprietary therapeutic pipeline 📈 Building something larger than a single drugOur clinical assets—including SJP-001—remain central to our near-term value creation. Atlas is designed to build upon that foundation by creating additional therapeutic opportunities, expanding our intellectual-property portfolio, supporting strategic collaborations, and potentially generating a repeatable pipeline of new drug candidates.This partnership helps Sen-Jam evolve from a company with a promising clinical pipeline into a scalable therapeutic-discovery platform.A data license alone does not create enterprise value. Enterprise value will be created by what our team discovers, validates, protects, and commercializes using that data. This partnership gives Atlas a significantly stronger foundation from which to do exactly that.We believe Sen-Jam’s future lies at the intersection of:🧬 Our scientific understanding of inflammation💊 Our experience developing repurposed combination therapeutics🤖 Our growing ability to apply computational intelligence at scaleThis is another meaningful step toward our mission: accelerating the discovery and delivery of therapeutics, increasing speed to patients, lowering development costs, and making life-changing medicines accessible to everyone on the planet.Thank you for your continued belief in Sen-Jam and for helping us build something that can become much larger than any single drug, indication, or company.🌍 Longer, healthier, and more resilient lives.Everyone wins!Jim